PPM1D is a prognostic marker and therapeutic target in colorectal cancer

Experimental and Therapeutic Medicine

Volumn 8, Issue 2, 2014, Pages 430-434

  Peng, Tian Shu ^a   He, Yong Heng ^a   Nie, Tian ^a   Hu, Xiang Dang ^a   Lu, Hai Yan ^a   Yi, Jian ^a   Shuai, Yun Fei ^a   Luo, Min ^a  

^a HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Biomarker; Colorectal cancer; PPM1D; Prognosis

Indexed keywords

BIOLOGICAL MARKER; LIPOFECTAMINE; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN PHOSPHATASE MAGNESIUM DEPENDENT 1 DELTA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION ASSAY; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MRNA EXPRESSION ASSAY; MTT ASSAY; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING;

EID: 84902577165     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1762     Document Type: Article

References (17)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ and van der Burg SH: Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines 10: 899-921, 2011.
4. Lu G and Wang Y: Functional diversity of mammalian type 2C protein phosphatase isoforms: new tales from an old family. Clin Exp Pharmacol Physiol 35: 107-112, 2008.
5. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, Lowe SW and Powers S: Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 31: 133-134, 2002.
6. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J and Imoto I: Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9: 1995-2004, 2003.
7. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T and Inazawa J: PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63: 1876-1883, 2003.
8. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E and Bulavin DV: The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 26: 2502-2506, 2007.
9. Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS and Ogino S: Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 19: 1944-1953, 2012.
10. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS and Ogino S: Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 305: 1685-1694, 2011.
11. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148, 2008.
12. Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, Kosuge T, Kanai Y, Hosoda F, Imoto I, Ohki M, Inazawa J and Hirohashi S: Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 98: 392-400, 2007.
13. Wang P, Rao J, Yang H, Zhao H and Yang L: Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas. J Surg Oncol 104: 679-684, 2011.
14. Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G and Choi J: Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat 101: 269-278, 2007.
15. Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J and Hayashi Y: Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci 102: 1101-1106, 2011.
16. Hu W, Feng Z, Modica I, Klimstra DS, Song L, Allen PJ, Brennan MF, Levine AJ, and Tang LH: Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 1: 360-368, 2010.
17. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA and Kim JY: Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 86: 245-256, 2008.